Loxo Oncology, part of Eli Lilly, partnered with Foghorn Therapeutics in a deal that enables the former to use the latter’s Gene Traffic Control platform to advance its pipeline of oncology medicines.
Eli Lilly forged a multi-year collaborative partnership with China-based Regor Therapeutics Group to discover and develop new therapies for metabolic disorders.
Carlsbad, Calif.-based Ionis Pharmaceuticals inked a collaboration deal with AstraZeneca to develop and commercialize eplontersen for transthyretin amyloidosis (ATTR).
The shares of Utah-based Recursion climbed on December 7 after the company announced entering into a “transformational collaboration” with Swiss pharma giant Roche valued in the billions of dollars to identify and develop up to 40 new medications for neuroscience and oncology.
Swiss drug giant Novartis and Belgian pharma company UCB announced a deal to co-develop and commercialize two products targeting Parkinson’s disease, UCB0599 and UCB7853.
Astellas and Dyno Therapeutics announced a research collaboration to develop next-generation adeno-associated virus (AAV) gene therapy vectors for skeletal and cardiac muscle using Dyno’s CapsidMap platform.
Gilead Sciences exercised options to three of Arcus Biosciences’ programs, and the two companies also added a research collaboration deal.
Pfizer Inc. said on November 18 the U.S. government would pay $5.29 billion for 10 million courses of the company’s experimental Covid-19 antiviral drug, as the country rushes to secure promising oral treatments for the disease.
The United States signed contracts worth about $1 billion for doses of the antibody-based Covid-19 treatment from Britain’s GSK and U.S.-based Vir Biotechnology, as countries seek to secure promising options beyond vaccines.
Union leaders representing 50,000 nurses and other U.S. medical staff reached a tentative agreement with Kaiser Permanente on November 13, averting a strike that could have disrupted patient care at hospitals.
